How have CDTTW shares performed in 2024?

Conduit Pharmaceuticals' stock was trading at $0.0693 at the beginning of 2024. Since then, CDTTW stock has increased by 1.0% and is now trading at $0.07. View the best growth stocks for 2024 here .

Are investors shorting Conduit Pharmaceuticals?

Conduit Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 38,900 shares, a decline of 6.7% from the March 15th total of 41,700 shares. Based on an average daily volume of 5,200 shares, the days-to-cover ratio is presently 7.5 days. View Conduit Pharmaceuticals' Short Interest .

How do I buy shares of Conduit Pharmaceuticals?

Shares of CDTTW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CDTTW

Conduit Pharmaceuticals (CDTTW) Stock Price, News & Analysis

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Free CDTTW Stock Alerts

$0.07

+0.02 (+40.00%)

(As of 05/2/2024 ET)

Compare

Today's Range: $0.07
▼
$0.09
50-Day Range: $0.04
▼
$0.14
52-Week Range: $0.01
▼
$0.18

Volume: 10,400 shs
Average Volume: 10,066 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get Conduit Pharmaceuticals alerts:

Ad Stansberry Research

Global crypto currency reset (41 major banks signed up)

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

CDTTW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CDTTW Stock News Headlines

October 30, 2023 | investorplace.com

Why Is Conduit Pharmaceuticals (CDT) Stock Up 66% Today?

See More Headlines

Receive CDTTW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conduit Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:CDTTW
CUSIP: N/A
CIK: 1896212
Web: www.conduitpharma.com
Phone: 760-471-8536
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. David Joszef Tapolczay (Age 65)
CEO & Director
Comp: $419.8k
Mr. Adam Sragovicz (Age 54)
Chief Financial Officer
Comp: $116.67k
Dr. Joanne M. Holland (Age 49)
Chief Scientific Officer

Key Competitors

View All Competitors

CDTTW Stock Analysis - Frequently Asked Questions

How have CDTTW shares performed in 2024?: Conduit Pharmaceuticals' stock was trading at $0.0693 at the beginning of 2024. Since then, CDTTW stock has increased by 1.0% and is now trading at $0.07.
View the best growth stocks for 2024 here.
Are investors shorting Conduit Pharmaceuticals?: Conduit Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 38,900 shares, a decline of 6.7% from the March 15th total of 41,700 shares. Based on an average daily volume of 5,200 shares, the days-to-cover ratio is presently 7.5 days.
View Conduit Pharmaceuticals' Short Interest.
How do I buy shares of Conduit Pharmaceuticals?: Shares of CDTTW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDTTW) was last updated on 5/3/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial